CardioVascular BioTherapeutics Revenue and Competitors

CardioVascular BioTherapeutics Inc. (CVBT) is a biopharmaceutical company, headquartered in Las Vegas, Nevada, currently focused on developing new drugs for the treatment of cardiovascular disease. Our protein drug candidate, CardioVascu-Grow™, is designed to facilitate growth of new blood vessels in the heart and other tissues and organs with impaired vascular systems. In two separate clinical trials in Germany in the mid-1990s that Dr. Thomas J. Stegmann conducted, a protein identical in structure to CardioVascu-Grow™ prompted the growth of new blood vessels in the heart and an increased pumping capacity of the heart in the patients treated. We are now working to confirm the medical benefits of this protein drug candidate through human clinical trials authorized by the U.S. Food and Drug Administration (FDA). Our clinical trial for no-option heart patients commenced in August 2004, with a network of six major medical centers now included in conducting these trials. CardioVascular BioTherapeutics, Inc. is committed to conducting additional clinical trials to establish the positive effect of our drug candidate aimed at improving the quality of life for those suffering from heart disease, stroke, diabetic wounds, or peripheral vascular disease, and pledges to continue exploration for additional applications of Cardio Vascu-Grow™.